T-cell replete haploidentical stem cell transplantation with low dose anti-thymocyte globulin for relapsed/refractory Ewing sarcoma family tumors.
Hideki SanoKazuhiro MochizukiShogo KobayashiYoshihiro OharaNobuhisa TakahashiShingo KudoKazuhiko IkedaHitoshi OhtoAtsushi KikutaPublished in: Cancer reports (Hoboken, N.J.) (2021)
In this study, three of the six patients with RR-ESFTs survived for more than one year without relapse, and the treatment toxicity was considered acceptable even for patients who underwent high-intensity pretreatment. TCR-haplo-SCT could be a potential therapeutic option for patients with RR-ESFTs.
Keyphrases
- stem cell transplantation
- high intensity
- high dose
- low dose
- ejection fraction
- resistance training
- prognostic factors
- newly diagnosed
- acute lymphoblastic leukemia
- immune response
- diffuse large b cell lymphoma
- peripheral blood
- patient reported outcomes
- acute myeloid leukemia
- hodgkin lymphoma
- bone marrow
- oxidative stress
- regulatory t cells
- replacement therapy